

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Lehmann-Lintz, T. et al Docket No.: 5/1272US  
Serial No. : To be Assigned ) Art Unit: To be Assigned  
Filed : March 14, 2002 ) Examiner: To be Assigned  
For : Substituted Piperazine Derivatives, the Preparation Thereof and Their Use  
as Medicaments

BOX PCT  
Commissioner for Patents  
Washington, D.C. 20231

March 14, 2002

**TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT**

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:

A certification as specified in 37 C.F.R. §1.97(e); or

The fee set forth in 37 C.F.R. §1.17(p).

The Assistant Commissioner is hereby authorized to charge payment of the \$240.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set forth in 37 C.F.R. §1.17(i).

The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,




Anthony P. Bottino  
Attorney for Applicant(s)  
Reg. No. 41,629

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 791-6764

EXPRESS MAIL LABEL NO. EL747494492US  
Deposited: March 14, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS  
BEING DEPOSITED WITH THE UNITED STATES  
POSTAL SERVICE "EXPRESS MAIL POST OFFICE  
TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE COMMISSIONER FOR  
PATENTS, WASHINGTON, D.C. 20231. BOX PCT

  
By: Anthony P. Bottino  
Reg. No. 41,629